Embody Review: The Cheapest Headline in This Market — From a Company the BBB Rates F

What Is Embody?

Embody is a direct-to-consumer telehealth brand selling compounded GLP-1 medication on a monthly subscription. You complete an online intake, a clinician reviews it, and if approved a compounded semaglutide or tirzepatide injection ships to you with supplies included. The company also runs ED (RodeoMeds), sermorelin, NAD+ and glutathione product lines under the same parent.

The pricing is the pitch and it is genuinely aggressive. The exclusive landing page advertises compounded semaglutide at $69/mo, marked down from $299, and compounded tirzepatide at $119/mo. Embody's standard published rates from 1 July 2026 are $79/mo and $129/mo respectively. Everything is month to month with no contract, and the price includes medication, insulin-sized needles and supplies, clinician review and free 1–2 day shipping. Embody states you can cancel a shipment at any time by email, and offers a full refund if your prescription is not approved.

Embody also discloses its regulatory position, which many competitors do not: 'Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality.' It says it uses US-based 503A compounding pharmacies.

Then there is the company record, and it is the reason this review is rated as it is. The BBB lists the operator as Modern Metabolic Medicine, Inc. of 1811 Silverside Rd Ste 260, Wilmington, DE, trading also as SnagRx and RodeoMeds, with a business start date of 19 December 2025 and a BBB file opened on 5 May 2026. It is not accredited and carries an F rating, stated reason: 'Failure to respond to 16 complaint(s) filed against business.' All sixteen remain unanswered.

Medications Offered & Pricing

Prices are as advertised on 6 August 2026. Treat the $69 and $119 figures with real caution. The most frequent complaint against this company, at the BBB and on Trustpilot, is that the rate charged at refill does not match the rate advertised at signup — one BBB complainant describes advertised rates in the $79–$199 range escalating sharply on the second charge. Embody's own standard rates are already $10 higher than the exclusive offer. Before you enter card details, screenshot the price you are being quoted, and check your second month's statement against it rather than assuming the promotional rate persists.

Brand-Name or Compounded?

Everything Embody sells in this category is compounded. There is no brand-name Ozempic, Wegovy, Mounjaro or Zepbound option. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality — Embody says this on its own site, which is more than several competitors manage.

One detail in that disclosure is worth unpacking, because it is doing more work than it appears. Embody says its medication comes from '503A compounding pharmacies' produced in 'FDA-regulated facilities.' Section 503A pharmacies compound for individually identified patients and are primarily overseen by state boards of pharmacy; they are not required to meet the federal current good manufacturing practice standards that apply to 503B outsourcing facilities, and they are not routinely FDA-inspected in the way a drug manufacturer is. 'FDA-regulated' is therefore accurate but considerably weaker than it sounds. If sterility and potency assurance matter to you — and for an injectable, they should — a provider using a 503B outsourcing facility offers a stronger position.

A BBB complaint against the company also raises an undisclosed-ingredient concern about an oral product combining tirzepatide with B12, questioning both what was in it and whether the combination had been tested. We cannot verify the specifics, but it is consistent with a pattern of thin disclosure about what is actually in the compounded preparations.

The Consultation Process

Eligibility

• •Embody states it serves all US states except Louisiana, and that in Nebraska services are limited to patients aged 19 or over. That is more specific state disclosure than most competitors publish.
• •No lab work is described as a requirement — the intake is questionnaire-based.
• •GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive.
• •Clinician judgement is required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •One BBB complainant reported being shipped a 0.25mg dose while established on 1.0mg. If a delivery does not match your prescribed dose, do not self-adjust to compensate — contact a clinician.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Free shipping with 1–2 day delivery advertised, including insulin-sized needles and injection supplies in the price. Bundling supplies is a genuine convenience that some competitors charge for separately.

• •Medication, supplies, clinician review and shipping bundled into one price
• •No contract — month-to-month billing
• •Free 1–2 day shipping
• •Full refund if your prescription is not approved
• •Cancellation by email at any time (per company policy)
• •Ongoing support from nursing staff
• •Clear state-availability disclosure
• •Explicit statement that compounded medication is not FDA-approved

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Embody May Be Best For

• •Honestly, very few people at present — the price advantage is real but the counterparty risk is high
• •Price-driven patients who will pay with a card they can charge back easily and who will verify month two before committing further
• •Anyone who has already used Embody without incident and simply wants to understand the record

Limitations

• •An F rating from the BBB is not the same as a poor rating. It is the grade given for not engaging at all, and here the stated reason is explicit: failure to respond to sixteen complaints, none of which has been answered. Plenty of companies in this market accumulate complaints; answering them is the minimum evidence that a customer with a problem has somewhere to go. On the record available, Embody customers do not.
• •The complaint pattern lands squarely on the thing the marketing sells. This is not a company with scattered service gripes — the recurring theme is that the advertised price is not the price charged at refill. That makes the $69 headline the least reliable number in this review, and it is the number the whole offer is built on. Screenshot everything and check your second statement.
• •The company is eight months old. Modern Metabolic Medicine, Inc. started trading on 19 December 2025 and its BBB file was opened in May 2026. A short history is not itself damning, but it means there is no track record of honouring commitments over time, and it makes the sixteen unanswered complaints a larger share of a smaller base.
• •The 503A detail matters more than it sounds. For a sterile injectable you are taking weekly for months, the difference between a state-regulated compounding pharmacy and a federally cGMP-regulated 503B outsourcing facility is a real difference in the assurance you have about sterility and potency. Embody's disclaimer is honest but the phrase 'FDA-regulated facilities' invites a stronger reading than the facts support.
• •To be fair to the company: the price genuinely is low, the inclusions are generous, the no-contract terms are good, the state disclosure is better than most, and refunding an unapproved prescription is the right policy. If the billing and complaint-handling were sound this would be a well-rated provider. They are not, and that is what the rating reflects.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

On paper Embody is a strong offer. $69/mo for compounded semaglutide with needles, supplies, clinician review and two-day shipping included, month to month with no contract and a full refund if you are not approved, is a better package than most of this market sells at twice the price. The FDA disclosure is honest and the state-availability detail is clearer than competitors bother with.

The problem is that none of that is worth much if the company does not honour it, and the available record says it frequently does not. An F rating from the Better Business Bureau for failing to respond to sixteen complaints — with all sixteen still unanswered — is not a middling score, it is the absence of any complaint-resolution process at all. And the complaints themselves land precisely on the offer: customers describing refill charges well above the rate they signed up at, cancellations requested and ignored, refunds promised and never paid, a money-back guarantee not honoured. The company has been trading since December 2025, so this record has accumulated in about eight months.

We rate Embody 2.0 out of 5. The pricing is excellent and the terms read well; the evidence that they are actually delivered is poor, and there is no visible path to escalate if they are not. That is a bad combination for a product you pay for monthly and inject weekly.

If low price is the priority, Bliv is comparable at $58/mo and CallonDoc is $89/mo with an A+ BBB rating and over a million patients served — a small premium for a company that answers the phone. If you use Embody anyway, pay with a card you can dispute, screenshot the quoted price, cancel in writing with proof, and check every statement.

This review is informational only and is not medical advice. Compounded GLP-1s are not FDA-approved and have not been evaluated for safety, efficacy or quality. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.